There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seagen (SGEN – Research Report) and Gain Therapeutics (GANX – Research Report) with bullish sentiments.
Seagen (SGEN)
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on Seagen, with a price target of $229.00. The company’s shares closed last Wednesday at $206.85, close to its 52-week high of $209.39.
According to TipRanks.com, Renza is a 4-star analyst with an average return of
Seagen has an analyst consensus of Hold, with a price target consensus of $229.00.
See the top stocks recommended by analysts >>
Gain Therapeutics (GANX)
H.C. Wainwright analyst Boobalan Pachaiyappan reiterated a Buy rating on Gain Therapeutics today and set a price target of $10.00. The company’s shares closed last Wednesday at $3.44.
According to TipRanks.com, Pachaiyappan has 0 stars on 0-5 stars ranking scale with an average return of
Gain Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.00, implying a 192.4% upside from current levels. In a report issued on August 28, BTIG also assigned a Buy rating to the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SGEN:
- Seagen says ‘OS, data, a secondary endpoint, are not yet mature’
- Seagen: TUKYSA trial in combo with Kadcyla meets primary endpoint of PFS
- Pfizer Stock’s (NYSE:PFE) Future: Not as Bleak as You’d Think
- Pfizer (NYSE:PFE) Seeks Greener Pastures to Boost Sales
- Seagen reports Q2 EPS ($1.13), consensus (78c)
